Candel Therapeutics reports $102.9M cash; updates on CAN-2409 BLA timeline and 2025 milestones

Candel Therapeutics, Inc.

Cash and equivalents $102.9M (unaudited) at Dec 31, 2024, vs $35.4M at end-2023; provides runway into Q1 2027.
CAN-2409 BLA submission for prostate cancer on track for Q4 2026; phase 3 data to be presented at upcoming scientific conference.
Updated overall survival data for CAN-2409 in pancreatic and lung cancer expected Q1 2025.
Phase 1b CAN-3110 overall survival data in recurrent high-grade glioma expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.